Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Somatostatinoma 1Ovarian Neoplasms 1Neurologic Manifestations 1Neuroendocrine Tumors 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Lung Neoplasms 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Brain Neoplasms 1Attention Deficit Disorder with Hyperactivity 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Cytidine Triphosphate × Clear all
NCT03412630 2023-11-24

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Eastern Cooperative Oncology Group

Phase NA Terminated
1 enrolled 1 chart
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡